Baader Bank Aktiengesellschaft Makes New $204,000 Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Baader Bank Aktiengesellschaft purchased a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 16,978 shares of the company's stock, valued at approximately $204,000. Baader Bank Aktiengesellschaft owned 0.05% of Delcath Systems at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. acquired a new stake in Delcath Systems during the third quarter valued at approximately $808,000. Virtu Financial LLC acquired a new stake in shares of Delcath Systems during the 3rd quarter worth approximately $289,000. Barclays PLC acquired a new stake in shares of Delcath Systems during the 3rd quarter worth about $104,000. Geode Capital Management LLC increased its stake in shares of Delcath Systems by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock valued at $2,275,000 after buying an additional 7,298 shares during the period. Finally, Jane Street Group LLC bought a new stake in Delcath Systems in the third quarter valued at approximately $110,000. Institutional investors own 61.12% of the company's stock.

Delcath Systems Trading Down 2.3 %

NASDAQ:DCTH traded down $0.37 during midday trading on Friday, hitting $15.60. 233,428 shares of the company traded hands, compared to its average volume of 466,929. The firm's fifty day moving average is $12.66 and its 200-day moving average is $10.44. The firm has a market capitalization of $498.73 million, a P/E ratio of -11.56 and a beta of 0.87. Delcath Systems, Inc. has a 12-month low of $3.70 and a 12-month high of $16.44.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DCTH. StockNews.com upgraded shares of Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. Stephens reiterated a "buy" rating on shares of Delcath Systems in a report on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Delcath Systems in a research note on Tuesday, January 14th. Finally, Craig Hallum increased their price target on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $22.25.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.